| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $13.4M | — | +75.0% |
| SG&A Expense | $6.6M | — | +111.9% |
| Operating Income | -$20.0M | — | -85.6% |
| Net Income | -$18.9M | — | -263.1% |
| EPS (Basic) | -$0.35 | — | +37.5% |
| EPS (Diluted) | -$0.35 | — | +37.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $20.5M | +95.4% | +263.8% |
| Short-term Investments | $86.9M | +0.9% | +1104.9% |
| Current Assets | $112.8M | +11.6% | +592.1% |
| Total Assets | $248.5M | +43.8% | +551.8% |
| Current Liabilities | $9.9M | -7.8% | +2.1% |
| Total Liabilities |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.3M | — | -83.0% |
| Capital Expenditures | $983K | — | — |
| Investing Cash Flow | -$65.6M | — | -1505.4% |
| Financing Cash Flow | $89.9M | — | — |
| Free Cash Flow | -$15.3M | — | — |
| $21.2M |
| -0.4% |
| +27.0% |
| Stockholders' Equity | $227.2M | +50.0% | +961.5% |